Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

29-02-2024(Thu) 28-02-2024(Wed) 27-02-2024(Tue) 26-02-2024(Mon) 23-02-2024(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
15 Jul, 2019 (Monday)

            
PUJIANG INTL(2060)
Analysis¡G
Pujiang International Group (2060) mainly provides materials for construction projects. It mainly has two business segments, namely, the Cable Business and Prestressed Materials Business. Its Cable Business mainly provides bridge cables for long-span bridges and super-long-span bridges and its Prestressed Materials Business mainly provides prestressed materials for various infrastructure constructions. Pujiang International Group is the largest provider of bridge cables for the construction of super-long-span bridges in China and the third largest prestressed materials manufacturer in China. It is projected that from 2018 to 2022, China`s fixed asset investment in tunnels and bridges will grow at a CAGR of 5.5% and 10.4% respectively. By 2022, super-long span bridges will total 194,representing a CAGR of 20.8% between 2018 and 2022 which will benefit the Group`s cable business. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $3.40, Target Price: $3.75, Cut Loss Price: $3.30


TRAD CHI MED(570)
Analysis¡G
The company`s main business is the development, production and sale of Chinese medicine and products in China. It is the listing platform for the Chinese medicine segment of Sinopharm Group. In 2018, the company`s turnover was RMB 11.26 billion, a YoY increase of 35%; the net profit attributable to shareholder was RMB 1.44 billion, showing a YoY increase of 23%. According to the company`s announcement on July 10, 2019, the company`s controlling shareholder, Sinopharm Group, increased its holdings of 20.39 million shares in the open market, with an average price of HKD 3.88 per share, which together accounted for 32.46% of the company`s shares afterwards. This action reflects the shareholder`s confidence in the company`s long-term development. In addition, it is expected that the company will build up a number of GMP bases in 2019, which shows the national layout is accelerating. With the steady growth of the concentrated TCM granules and finished drugs businesses, the smooth integration of the TCM decoction pieces business, and the cooperation of warehousing logistics with Ping An company, which will bring synergy to the company and build up a solid foundation for future development.
Strategy¡G
Buy-in Price: $ 3.59, Target Price: $ 4.50, Cut Loss Price: $ 3.45



Bosideng(3998.HK) - high-end fashion transformation helping GPM expansion¡Ae-commerce business with fast growing

Investment Summary

Bosideng's annual revenue for FY 2018 increased by 16.9% y.o.y., slightly higher than our expectation. The revenue of the largest business branded down apparel increased by 35.5% y.o.y., mainly due to the increase of the proportion of medium and high-end products in the product mix, which led to the increase in ASP. There is not much growth in sales volume. The management team's goal this year is to make both sales volume and ASP to be the drivers of revenue growth. Medium to high-end products with a price exceeding $1800 accounted for 25% of the branded down apparel business last year, and this proportion is expected to increase further this year.

 The OEM business grew by 46.1%y.o.y. last year, and the management team's earlier guidance was over 20%. Facing the Sino-US trade wars, it says that the impact is limited and customers are more concerned about the global business. Revenue of ladieswear business increased by 4.19%, which is lower than the medium to high single digits of the guidelines. This year is expected to maintain steady growth and achieve low single-digit growth.

GPM of FY2018 improved by 6.7 ppt y.o.y. to 53.1%, reflecting the increase in the proportion of medium to high-end products. Distribution and administration increased by 35.3% y.o.y., and the percentage share to revenue also increased by 5.4 ppt to 40.1%, mainly due to the company's efforts in brand building and channel optimization for the branded down apparel business and strategic transformation.

For the e-commerce business, the revenue of brand down apparel and ladieswaer business increased by 55.6% and 11.8% y.o.y. respectively, accounting for 23.1% and 5.6% of the revenue from the branded down apparel business and ladieswear business. The company plans to introduce more products which are exclusively offered online, gradually diversify the features of online goods and expand the product portfolio, while increase the sales proportion of the age group of 25-35. We expect the e-commerce business will maintain rapid growth, and the percentage share of brand down apparel online business is expected to rise to one-third.

As at March 31, 2019, the total number of selling points of the company's down apparel business (net) increased by 162 to 4,628 compared to that of last year. Last year, 40% of the shops were remodeled, and the rest are expected to be rebuilt in the next two years. This year the company plans to open about 1,000 stores, but it will also shut down 600 to 700 inefficient stores.

Short-selling agency Bonitas Research has recently released reports. Alleging Bosideng that insiders conducted fake inter-company transactions through a maze of direct and indirect subsidiaries, overpayment for multiple aquisitions to undisclosed insiders, and disposal of assts without receipt of payment.

Bosideng has issued clarification announcements, and the share price has since rebounded. During the annual result announcement conference, the management team also states that the chairman owns a number of asset businesses outside the listed company and will consider selling these off-balance sheet assets, including factories, to the listed company. It will also continue to pay attention to M&A opportunities, and the targeted items will contain outdoor functional, fashionable and technological elements.We give target price-earnings ratio 21 times, with target price HKD2.7. (current price as of July 11, 2019)

Investment Thesis & Valuation

We give accumulate rating, target price-earnings ratio 21 times, with target price HKD2.7. Potential investment risks include revenue growth or channel expansion missing expectation, raw material cost with huge volatility. (current price as of July 11, 2019)

Financials

Click Here for PDF format...




Recommendation on 15-7-2019
RecommendationAccumulate
Price on Recommendation Date$ 2.580
Suggested purchase priceN/A
Target Price$ 2.700
Writer Info
Tracy Ku
(Research Analyst)
Tel: +852 2277 6516
Email:
tracyku@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]